These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21651388)

  • 1. New FDA regulation to improve safety reporting in clinical trials.
    Sherman RB; Woodcock J; Norden J; Grandinetti C; Temple RJ
    N Engl J Med; 2011 Jul; 365(1):3-5. PubMed ID: 21651388
    [No Abstract]   [Full Text] [Related]  

  • 2. New regulatory rules for clinical trials in the United States and the European Union: key points and comparisons.
    Miossec M; Miossec P
    Arthritis Rheum; 2006 Dec; 54(12):3735-40. PubMed ID: 17133535
    [No Abstract]   [Full Text] [Related]  

  • 3. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 4. Making clinical trials safer for human subjects.
    Baram M
    Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
    [No Abstract]   [Full Text] [Related]  

  • 5. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory science as culture: contested two-dimensional values at the US FDA.
    Abraham J
    Sci Cult (Lond); 2002 Sep; 11(3):309-35. PubMed ID: 15971364
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 8. MedWatch, the new FDA adverse effects reporting system.
    Shader RI; Greenblatt DJ
    J Clin Psychopharmacol; 1993 Oct; 13(5):303-4. PubMed ID: 8227487
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to safety data--stockholders versus prescribers.
    Pfeffer MA; Bowler MB
    N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642
    [No Abstract]   [Full Text] [Related]  

  • 11. Researcher accused of not reporting adverse events: U.S. v. John S. Najarian (Part 1).
    Maloney DM
    Hum Res Rep; 2002 Aug; 17(8):8. PubMed ID: 12731496
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA: regulators or abdicators?
    Lancet; 2010 Oct; 376(9748):1196. PubMed ID: 20934577
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA clinical trial process: effectuating change in the regulatory framework governing clinical trials to account for the historical shift from "traditional" to "new" phase I trials.
    Aldes JL
    Health Matrix Clevel; 2008; 18(2):463-500. PubMed ID: 19739574
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving the reporting of adverse drug reactions in the hospital setting.
    Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
    Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA to weigh test of blood substitute out of public view.
    Burton T
    Wall St J (East Ed); 2006 Jul; ():D3. PubMed ID: 16906688
    [No Abstract]   [Full Text] [Related]  

  • 20. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.